Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
J Oncol Pharm Pract. 2021 Jul;27(5):1235-1244. doi: 10.1177/1078155221991636. Epub 2021 Feb 2.
Breast cancer is responsible for most of the cancer-induced deaths in women around the world. The current review will discuss different approaches of targeting HER2, an epidermal growth factor overexpressed in 30% of breast cancer cases.
We conducted a search on Pubmed and Scopus databases to find studies relevant to HER2+ breast cancers and targeting HER2 as means of immunotherapy. Out of 1043 articles, 105 studies were included in this review.
As well as the introduction of HER2 and breast cancer subtypes, we discussed various aspects of HER2-targeting immunotherapy including monoclonal antibodies, Antibody-drug conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cells and vaccines.
Despite several ways of controlling breast cancer, the need to investigate new drugs and approaches seems to be much significant as this cancer still has a heavy burden on people's health and survival.
乳腺癌是导致全世界女性癌症死亡的主要原因。本综述将讨论针对 HER2 的不同方法，HER2 是 30%乳腺癌病例中过度表达的表皮生长因子。
我们在 Pubmed 和 Scopus 数据库上进行了搜索，以找到与 HER2+乳腺癌和针对 HER2 作为免疫疗法手段相关的研究。在 1043 篇文章中，有 105 项研究纳入了本综述。
除了介绍 HER2 和乳腺癌亚型外，我们还讨论了 HER2 靶向免疫疗法的各个方面，包括单克隆抗体、抗体药物偶联物 (ADC)、嵌合抗原受体 (CAR) T 细胞和疫苗。
尽管有几种控制乳腺癌的方法，但似乎仍需要研究新的药物和方法，因为这种癌症仍然对人们的健康和生存造成沉重负担。
